KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Ontology highlight
ABSTRACT: The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 (a PD-L1/CTLA-4 targeted bispecific antibody).
DISEASE(S): Her2-positive Colorectal Cancer,Biliary Tract Neoplasms,Colorectal Neoplasms,Her2-positive Biliary Tract Cancer
PROVIDER: 70605 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA